A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With Paclitaxel vs. Paclitaxel Alone in Patients With Metastatic or Locally Recurrent Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Alisertib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Feb 2020.
- 16 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Feb 2020.
- 18 Dec 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.